Veracyte Q2 FY26 swings to GAAP net income of $25.5 million; revenue rises 15% to $150.3 million
Reuters2026/07/30 20:27- Veracyte posted Q2 2026 GAAP net income of $25.5 million, swinging from a loss; diluted GAAP EPS was $0.31.
- Revenue rose 15% year over year to $150.3 million; testing revenue climbed 19% to $145.7 million.
- Adjusted EBITDA increased 23% to $44 million, lifting adjusted EBITDA margin to 29.2% from 27.5%.
- Total volume grew 13% to 50,967 tests, driven by Decipher testing revenue up 20% to $91.9 million.
- Raised 2026 revenue outlook to $590 million-$596 million; CEO Marc Stapley cited new launches Prosigna LDT, TrueMRD for MIBC.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Ivy League’s space gamble: Harvard reveals $2.2 billions SpaceX position, its largest single stock holding
Harvard University Investment Management Company disclosed that it holds $2.2 billion worth of SpaceX shares, making it the largest single stock position in its $4.3 billion US equity portfolio. This holding originated from Harvard’s early investment in SpaceX through venture capital funds, and the position has significantly appreciated after SpaceX’s public listing in June this year. The University of California also disclosed a roughly $1 billion position in SpaceX during the same period. Over the past decade, endowment funds from several universities have made substantial bets on private tech assets.
Circle obtains Major Payment Institution license in Singapore
Crypto prices
More
